The American Medicine Safety and Security Act would impose new employment and post-employment restrictions on the Food and Drug Administration (FDA) aimed at limiting ties to what the bill defines as “foreign countries of concern”: the People’s Republic of China, Russia, and Iran. It would bar nationals of those countries from FDA employment or paid work arrangements, require FDA workers to report immediate family members who are nationals of those countries, and require termination for failure to report. The bill also would require current and future FDA employees to agree that, for 10 years after leaving the agency, they may not work for or volunteer with any entity based in a foreign country of concern.
Impact
The bill would add significant new eligibility, disclosure, and post-employment restrictions for FDA personnel, especially those involved in reviewing drug and device approvals, clearances, licensure, or authorizations. It would also limit access to certain drug and device information within the agency for employees with immediate family ties to a foreign country of concern or prior work experience with an entity based there. In practice, the measure would affect FDA hiring, retention, confidentiality/access rules, and revolving-door employment opportunities, while creating new compliance obligations for both employees and the agency.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes, the available context suggests the bill is framed as a national security and supply-chain integrity measure focused on protecting the safety and security of drugs and devices. The title and provisions indicate a strong precautionary approach toward foreign influence at the FDA. Because there are no transcripts or votes provided, there is no documented bipartisan or partisan reaction in the supplied materials, and no formal sentiment can be inferred beyond the sponsor’s stated security rationale.
Contention
The main points of contention are likely to be the breadth and rigidity of the restrictions, including the categorical ban on nationals of China, Russia, and Iran from FDA employment, the mandatory reporting of immediate family members’ nationality, and the 10-year post-employment ban on work for entities in those countries. Critics could view these provisions as overinclusive, potentially discriminatory, and disruptive to FDA recruitment and expertise, while supporters would likely argue they are necessary to prevent foreign influence, espionage, or data leakage in sensitive drug and device review functions. The bill also raises privacy and due process concerns because failure to report family ties triggers immediate termination.
To Mandate The Use Of Biosimilar Medicines Under Health Benefit Plans; To Require A Healthcare Provider To Prescribe Biosimilar Medicines; And To Improve Access To Biosimilar Medicines.